Stockscreener 앱 받기
248.50
0.92%
2.27
시간 외 거래:
248.50
전일 마감가:
$246.23
열려 있는:
$243.63
하루 거래량:
650.36K
Relative Volume:
0.99
시가총액:
$16.30B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
28.01
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
-2.71%
1개월 성능:
-6.43%
6개월 성능:
+14.88%
1년 성능:
+29.40%
1일 변동 폭
$240.64
$249.52
1주일 범위
$240.64
$258.55
52주 변동 폭
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
248.50 | 16.76B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen - marketbeat.com
Allspring Emerging Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth - simplywall.st
Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS - marketbeat.com
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call - Sahm
Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital. - Pluang
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says - marketscreener.com
RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating - marketscreener.com
Ascendis Pharma doubles sales, significantly boosting profit - medwatch.com
Ascendis Pharma AS earnings beat by €1.32, revenue topped estimates - Investing.com Nigeria
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Re - GuruFocus
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ... - Yahoo Finance
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength By Investing.com - Investing.com South Africa
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength - Investing.com Nigeria
Artisan Partners (ASND holder) discloses 2.63M Ascendis Pharma shares in 13G/A - Stock Titan
Ascendis Pharma's Long-Term Potential Intact, Wedbush Says - marketscreener.com
Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost - Quiver Quantitative
Ascendis Pharma A/S Q2 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Ascendis Pharma tops Q2 2026 estimates as launches gain - Investing.com
ASND: Q2 revenue more than doubled year-over-year, fueled by strong TransCon product demand and robust launches - TradingView
Ascendis Pharma A/S reports results for the quarter ended June 30Earnings Summary - TradingView
Ascendis Pharma (ASND) posts Q2 2026 profit on revenue surge and PRV sale - Stock Titan
Ascendis Pharma: Product Revenue Surges 105% To €315 Million As Adjusted Operating Profit Turns Positive - Pulse 2.0
Ascendis Pharma A/S Q2 2026 Earnings Call Transcript - MarketBeat
Ascendis Pharma's Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
Ascendis Pharma (ASND) posts €836M H1 profit and redeems $575M converts - Stock Titan
Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale - TradingView
Earnings Flash (ASND) Ascendis Pharma Posts Q2 Non-IFRS EPS 0.90 Euros, vs. FactSet Est of 1.80 Euros - marketscreener.com
Ascendis Pharma Reports Second Quarter 2026 Financial Results - The Manila Times
Ascendis Pharma Reports More Than 220 U.S. YUVIWEL Enrollments - Stock Titan
Ascendis Pharma (ASND) issues 15,060 staff warrants at $254.57 strike price - Stock Titan
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today - Benzinga
Ascendis Pharma A/S expected to post earnings of €1.38 a shareEarnings Preview - TradingView
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup - ChartMill
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), Scholar Rock Holding (SRRK) and Ascendis Pharma (ASND) - The Globe and Mail
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300 - Moomoo
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Buy" from Analysts - marketbeat.com
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 - Yahoo Finance
Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says - Yahoo Finance
Ascendis reports trial data for achondroplasia treatments By Investing.com - Investing.com Nigeria
Ascendis Pharma (ASND) reports new TransCon CNP achondroplasia trial data - Stock Titan
Ascendis Pharma (ASND) Could Be 20% Undervalued Following Its Recent Pullback - simplywall.st
Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia - HCPLive
Ascendis Pharma reports strong growth and safet... - Pluang
Ascendis Announces COACH Week 78 Results and Provides - GlobeNewswire
Ascendis plans Aug. 13 webcast before U.S. markets open - Stock Titan
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling A 26% Upside Potential - directorstalkinterviews.com
Defilade Capital Management L.P. Lowers Position in Ascendis Pharma A/S $ASND - MarketBeat
First Trust Advisors LP Acquires 18,905 Shares of Ascendis Pharma A/S $ASND - marketbeat.com
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):